Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Trump’s ‘most-favored nation’ drug-pricing plan hits a snag  

By Brian Buntz | December 30, 2020

Image from Wikimedia

A federal judge in Maryland has temporarily blocked a Trump executive order that tied Medicare reimbursement for several drugs to lower rates in other countries.

The executive order was facing a flurry of lawsuits. 

U.S. District Judge Catherine C. Blake sided with the plaintiffs’ argument that the Department of Health and Human Services (HHS) did not allow a public comment period when finalizing the rule and granted a temporary restraining order against the pricing scheme. 

The plaintiffs in the case included the Association of Community Cancer Centers (ACCC) and the Pharmaceutical Research and Manufacturers of America (PhRMA) trade association, among others. 

The executive order was slated to go into effect on Jan. 1, 2021. 

Centers for Medicare and Medicaid Services (CMS), an HHS department, had published an advance notice of proposed rulemaking in 2018, but later withdrew it as the president sought to pass legislation to address high drug pricing. 

The government later tried to bypass the public comment period, claiming it had a “good cause” to do so. In particular, the government argued that the COVID-19 pandemic contributed to a Medicare drug-pricing emergency. 

Judge Blake disagreed, stating the government’s plan to use the good cause exception “falls flat,” and arguing the government did not explain how Medicare recipients would see short-term economic relief.  

CMS published an update of its pricing scheme for 50 Medicare Part B drugs with international pricing controls on Nov. 27. The plan would add more drugs over a seven-year timeframe. The government projected the plan would cut Medicare spending in the first year by almost $5 billion.   

“Because the government is protected by sovereign immunity and no monetary damages are available, these severe economic losses can qualify as irreparable harm,” concluded Judge Blake in her opinion. 

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Genentech roche
Roche, Genentech to build $700M drug manufacturing plant in North Carolina
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
Roche
Roche to invest $50B in U.S. over next five years
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE